Group 1: Pain Management and Drug Mechanism - The mechanism of action for dihydroetorphine hydrochloride is more targeted compared to traditional opioids like fentanyl, as it has a significantly higher affinity for mu-opioid receptors [2] - The technology for sustained-release or modified-release formulations is universal and not specific to a single drug, with experience in conventional and abuse-deterrent formulations [2] Group 2: Addiction and Abuse Risk - The addiction and abuse potential of analgesics is closely related to their pharmacological effects, rather than their pharmacokinetics or metabolic pathways, indicating the importance of drug release control and individualized dosing [3] Group 3: Antivertigo Drug Development - The central mechanism of action for phenylpropanolamine hydrochloride involves blocking acetylcholine at M and N receptors, resulting in central and peripheral anticholinergic effects [4] - Research is ongoing to expand indications beyond motion sickness, targeting conditions like Meniere's disease and vestibular neuritis [5] Group 4: Weight Management Drug Comparison - Naltrexone is the only approved drug for weight management in China, acting by antagonizing opioid receptors to suppress eating impulses, differing from the overseas combination product Contrave [6][7] Group 5: mRNA Vaccine Development - The mRNA vaccine utilizes an LNP delivery system, achieving high immunogenicity through a combination of delivery system optimization, antigen design, and immune strategy [8] - The company claims advantages in antigen design, immune durability, and thermal stability compared to competitors, although there is currently no IND or clinical submission timeline [8]